



September 22, 2016
FOR 8:30 AM RELEASE
CSE:GCI

PhytoPain Pharma Announces Interview with Radio-Canada regarding its Development of a Prescription Marijuana Drug

Ottawa, Ontario - (Marketwired – September 22, 2016) – PhytoPain Pharma (“**PPP**”), a subsidiary of GrowPros Cannabis Ventures Inc. (“**GrowPros**” or the “**Company**” or “**GCI**”) (CSE:GCI), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it gave an interview to the journalist Brigitte Bureau of Radio-Canada regarding the development of a prescription marijuana drug. Shareholders can view the interview on CBC’s website at <http://ici.radio-canada.ca/regions/ottawa/2016/09/21/008-marijuana-medicinale-legalisation-gouvernement-trudeau.shtml>

According to Dr. G. Chamberland, Chief Scientific Officer, “*PPP is developing a prescription drug marijuana product for consumption via inhalation “smoking”. As part of its mission of bringing botanical-based therapies to patients with chronic diseases while maintaining the characteristics and properties of natural health products but backed by the scientific research and development of Pharma industry. Over the next years, the corporation is planning to develop the evidence to support the prescription of marijuana by physicians and to seek coverage by provincial and federal insurers.*” “*By implementing this approach, we believe that PPP is addressing the missing link that has existed for years as the major barrier of access to medical cannabis by both patients and physicians across the globe*”, commented Ryan Brown, Vice-President of Business Development and Director of Communications for GCI.

Dr. Chamberland further commented that the company intends on submitting a Clinical Trial Application later this year (pre-CTA submitted in August 2016 as per previous news release) and when authorized by Health Canada would initiate its Phase I trial in humans later this year. “*PPP001 is in its early stages of development, but based on published clinical trial data, the company is confident that it can bring this product to the market after completing the studies required by regulatory agencies*”, commented Dr. Chamberland.

For further information, please contact GrowPros Cannabis Ventures Inc.

Dr. Guy Chamberland	André Audet	Ryan Brown
Chief Scientific Officer	Executive Chairman	President, GrowPros MMP Inc.
Phone: (514) 220-9225	Phone: (613) 421-8402	Phone: (613) 421-8402

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.